𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Protective efficacy of hepatitis B vaccines in neonates

✍ Scribed by Francis E. André; Arie J. Zuckerman


Publisher
John Wiley and Sons
Year
1994
Tongue
English
Weight
890 KB
Volume
44
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

A literature search was carried out to investigate the factors that influence the protective efficacy (PE) of hepatitis B vaccines when given to neonates of hepatitis B surface antigen and e antigen positive mothers. Hepatitis B vaccines with either high or low antigen doses are very effective in preventing chronic hepatitis B infection in neonates at risk, but there is evidence that with lower dosages simultaneous use of hepatitis B immune globulin (HBIG) administration is more important than with higher dosages to elicit good protection (PE ≧ 90%). There is also a tendency for lower dosages to confer high PE less consistently, with noticeably greater numbers of chronic surface antigen carriers in neonates who received a complete vaccination course. Furthermore vaccination courses with higher vaccine dosages give high PEs, without concomitant HBIG administration at birth, provided that the first vaccine dose is given at birth and that the second dose follows within 2 months. © 1994 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Protective efficacy, immunotherapeutic p
✍ Jane N. Zuckerman 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB

Hepatitis B vaccines are highly effective and safe and have been incorporated into national immunization programs in over 150 countries. The major humoral immune response is to the common a determinant of the surface antigen protein of the virus. Approximately 5-10% of healthy immunocompetent subjec

Efficacy of hepatitis B vaccine against
✍ Saleem Kamili; Vitini Sozzi; Geoff Thompson; Katie Campbell; Christopher M. Walk 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 579 KB

Hepatitis B virus (HBV) mutants resistant to treatment with nucleoside or nucleotide analogs and those with the ability to escape from HBV-neutralizing antibody have the potential to infect HBV-vaccinated individuals. To address this potential serious public health challenge, we tested the efficacy

Large-scale efficacy trials of hepatitis
✍ Dr. Wolf Szmuness 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 English ⚖ 867 KB

The protocols of three placebo-controlled, randomized, double-blind clinical trials to assess the efficacy of an inactivated hepatitis B vaccine in dialysis patients and staff, and in male homosexuals are described. Based on the projected attack rates of HBV in the controls, the vaccine efficacy and